APR 1 1 2005

beby certify that this correspondence is being deposited with the U.S. Postal avice with sufficient postage as First Class Mail, in an envelope addressed to commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312 1250, on the

date shown below.

Dated: April 6, 2005

Signature:

(Harvey L. Cohen)

Docket No.: SCHERING 3.0-122 CIP (PATENT)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Anil Saksena

Application No.: 10/052,386

Group Art Unit: 1653

Filed: January 18, 2002

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE

PROTEASE INHIBITORS OF

HEPATITIS C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: April 6, 2005

Respectfully submitted,

Harvey L. Cohen

Registration No.: 28,365 LERNER, DAVID, LITTENBERG,

KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-458\

556115

PTO/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are require

Substitute for form 1449A/B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of

Complete if Known				
Application Number	10/052,386-Conf. #5995			
Filing Date	January 18, 2002			
First Named Inventor	Anil Saksena			
Art Unit	1653			
Examiner Name	R. B. Mondesi			
Attorney Docket Number	SCHERING 3.0-122 CIP			

U.S. PATENT DOCUMENTS					
Examiner Initials* Cite No.1 Number-Kind Code² ( if known)		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
iniuais	INO.	Country Code -Number -Nina Code (ii known)	MIM-DD-YYYY		or redevarier igures / epear	


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials			T <sup>2</sup>		
	CA	Patel et al., Activated Ketone Based Inhibitors of Human Renin, Journal of Medicinal Chemistry, 1993, Volume 36, Number 17, August 20, 1993, pages 2431-2447			
	СВ	Asano et al., Novel Retrovirus Protease Inhibitors, RPI-856 A, B, C and D, The Journal of Antiobiotics, Volume 47, No. 5, pages 557-565 (1994)			
	СС	Suto et al., Peptide Inhibitors of IKB Protease: Modification of the C-Termini of Z-LLF-CHO, Bioorganic & Medicinal Chemistry Letters, Vol. 6, No. 24, pp. 2925-2930 (1996)			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	 

<sup>&</sup>lt;sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



Docket No.: SCHERING 3.0-122 CIP (PATENT)

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Anil Saksena

Application No.: 10/052,386

Group Art Unit: 1653

Filed: January 18, 2002

Examiner: R. B. Mondesi

For: NOVEL PEPTIDES AS NS3-SERINE

PROTEASE INHIBITORS OF HEPATITIS

C VIRUS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge deposit account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our deposit account No. 12-1095.

Dated: April 6, 2005

04/12/2005 CCHAU1 00000024 121095 10052386

180.00 DA

Respectfully submitted,

Harvey L. Cohen

Registration No.: 28,365 LERNER, DAVID, LITTENBERG, KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant

LD-453\

01 FC:1806

556113